Survival outcomes of management in metastatic gastric adenocarcinoma patients
© 2021. The Author(s)..
Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan-Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44-0.51), 1.22 (95% CI 1.1-1.36), and 3.23 (95% CI 3.01-3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Scientific reports - 11(2021), 1 vom: 30. Nov., Seite 23142 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Huang-Ming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-021-02391-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333856597 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333856597 | ||
| 003 | DE-627 | ||
| 005 | 20231226203916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-021-02391-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333856597 | ||
| 035 | |a (NLM)34848751 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Huang-Ming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survival outcomes of management in metastatic gastric adenocarcinoma patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2022 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan-Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44-0.51), 1.22 (95% CI 1.1-1.36), and 3.23 (95% CI 3.01-3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Tsai, Hui-Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Hsiu-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, Su-Shun |e verfasserin |4 aut | |
| 700 | 1 | |a Shan, Yan-Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Hung-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Chao, Yee |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jen-Shi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shu-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Chiang, Chun-Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Anna Fen-Yau |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hsiu-Po |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tsang-En |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Li-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ming-Shiang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Li-Tzong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tsang-Wu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yi-Hsin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 11(2021), 1 vom: 30. Nov., Seite 23142 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g day:30 |g month:11 |g pages:23142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-021-02391-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 1 |b 30 |c 11 |h 23142 | ||